1Fillat C, Carrio M, Cascante A, et al. Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application.Curr Gene Ther, 2003, 3(1):13-26.
2Yazawa K, Fisher WE, Brunicardi FC. Current progress in suicide gene therapy for cancer. World J Surg, 2002,26(7):783-789.
3Komata T, Kanzawa T, Kondo Y, et al. Telomerase as a therapeutic target for malignant gliomas. Oncogene, 2002,21(4):656-663.
4Matias-Guiu X, Prat J. Molecular pathology of ovarian carcinomas. Virehows Arch, 1998, 433:103-111.
5Kyo S, Kanaya T, Takakura M, et al. Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors. Int J Cancer, 1999, 80:804-809.
6Dome JS, Look AT. Three molecular determinants of malignant conversion and their potential as theraputic targets.Curr Opin Oncol, 1999, 11:58-67.
7Takakura M, Kyo S, Kanaya T, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for trascriptional activation in immortalized and cancer cells. Cancer Res, 1999, 59:551-557.
8Horikawa I, Cable PL, Mshari C, et al. Cloning and characterization of the promoter region of human telomerase reverse transeriptase gene. Cancer Res, 1999, 59:826-830.
9Horikawa I, Cable PL, Mazur SJ, et al. Downstream Ebox-mediated regulation of the human telomerase reverse transeriptase (hTERT) gene transcription: evidence for an endogenous mechanism of transcriptional repression. Mol Biol Cell, 2002, 13(8):2585-2597.
